A R T I C L E I N F O
Introduction
The two causative agents of human African trypanosomiasis (HAT), i.e. Trypanosoma brucei (T.b.) rhodesiense and T.b. gambiense are endemic in sub-Saharan Africa. 1, 2 The drugs against HAT currently available on the market have major disadvantages, including limited clinical efficacy in certain disease stages, complex administration protocols and toxicity. 1, [3] [4] [5] Additionally, the small repertoire of available drugs against HAT suffers from emerging drug resistance. [6] [7] [8] [9] [10] While the number of new HAT cases has dropped considerably in the last few years, 11 there remains an interest in developing novel and non-toxic trypanocidal agents. [6] [7] [8] [9] [10] Several enzymes have been identified as potential targets for development of such new treatments. [12] [13] [14] [15] [16] For example, T. brucei 3′5′cyclic nucleotide phosphodiesterase B1 and B2 (TbrPDEB1 and TbrPDEB2) have been validated as essential enzymes of the parasite and can be exploited as a drug target. 16, 17 The high sequence homology (88%) between the catalytic sites of the TbrPDEB1 and B2 creates a high degree of equipotency against the paralogues. [17] [18] [19] However, selectivity for the parasite PDE over the human orthologues, especially human PDE4 (hPDE4), is required to limit unwanted side effects (e.g. emesis, gastrointestinal disturbance and immune suppression). [19] [20] [21] [22] [23] Over the years, several studies reported different hPDE4 inhibitors as starting point for TbrPDEB1 inhibitors, resulting in a number of potent inhibitors, e.g. cilomilast analogue 2 and rolipram analogue 4 ( Fig. 1 ). 19, 24 However, selectivity for TbrPDEB1 over hPDE4 in combination with antiparasitic activity has been a challenge. 19, 24 domain of TbrPDEB1 shows that the glycinamide tail occupies the Ppocket thereby explaining the observed selectivity for TbrPDEB1 over hPDE4 (Fig. 2) . 25 Successful targeting of the P-pocket was also observed in the crystal structure of TbrPDEB1 co-crystallized with NPD-937 (6, PDB: 5L8Y), indicating that a longer and more spacious tail group is also able to enter the P-pocket resulting in selectivity for TbrPDEB1 over hPDE4 (TbrPDEB1 pK i = 6.4 vs hPDE4 pK i = 5.5). 25 However, 5 and 6 show an unfortunate reduced phenotypic activity against T. brucei (pIC 50 = 5.3 and pIC 50 = 5.1, respectively), thereby halting further development of these compounds as trypanocidals. 25 Further research to replace the phenyl linker and tail group of 5 by an alkynamide resulted in the discovery of NPD-048 (7) which displays a submicromolar potency against TbrPDEB1 (TbrPDEB1 pK i = 6.2). 27 Although this alkynamide does not show a similar activity profile (hPDE4 pK i = 6.5) as observed with 5, the phenotypic activity against T. brucei (pIC 50 = 6.0) improved considerably compared with 5. Moreover, the co-crystal structure of 7 (PDB: 6FTM) in the catalytic domain of TbrPDEB1 indicates that the scaffold forms a good bidentate interaction with the conserved glutamine residue Gln874 while the alkynamide nitrogen atom offers a promising vector to grow the compound towards the Ppocket. 27 Herein, we report the structure-based design of new alkynamide tetrahydrophthalazinones with different amide substituents in an attempt to obtain ligands with a better antiparasitic activity.
Results and discussion

In silico exploration of the amide vector
The crystal structures of TbrPDEB1 ligated with 5, 6 and 7 (PDBcodes 5G2B, 5L8Y, and 6FTM respectively) 25, 27 were used to explore suitable amines to decorate the scaffold of 7 to fit the vector towards the P-pocket described by the alkynamide. All three crystal structures were used as basis because the P-pocket volume varies, indicating the flexibility of the P-pocket residues. Reaxys was used to extract all commercially available (eMolecules) primary or secondary amines with a molecular mass below 158 Da. Using the combinatorial library module of Molecular Operating Environment (MOE) software package of Chemical Computing Group, the amines were virtually coupled to the alkyne tetrahydrophthalazinone scaffold to make a combinatorial library consisting of 16,153 substituted alkynamides. These molecules were docked using PLANTS 28 into each of the three aforementioned TbrPDEB1 structures and all resulting docking poses were scored using Interaction Fingerprints 29 (IFP) for the core scaffold of the molecules. After applying combined scoring cut-offs 30 (PLANTS ≤ −90 and IFP ≥ 0.5) and filtering for binding poses in which the ligand was in contact with Gln874, there were 2291 unique molecules left. The docking results of the 3 different crystal structures were compared and the overlapping hits were visually inspected (see Fig. 3A ). Six compounds, consisting of aliphatic and aromatic substitutions of variating complexity, were hits in all three sets of docking results (Fig. 3B ). Compounds with a second (primary or secondary) amine or additional chiral centre were removed from the results to increase synthetic feasibility and to eliminate compounds with more than two diastereomers, nominating only 11 and 12 for synthesis. Non-chiral amines that were hits in two of the three sets of docking results (88 compounds) contained a higher abundancy of aromatic tail groups (66%) versus aliphatic tail groups (33%), thereby predicting a better occupancy of the P-pocket by aromatic groups than aliphatic groups. Most amines contained a second heteroatom that can function as a hydrogen bond acceptor, but no clear preference for flexible or (ring) strained amines was observed. These results were used as inspiration for the compounds synthesized from readily available amines. Fig. 1 . Repurposing hPDE4 inhibitors for the development of potent TbrPDEB1 inhibitors for the treatment of human African trypanosomiasis. 19, 24 Fig. 2. The structures of the reported tetrahydrophthalazinone-based TbrPDEB1 inhibitors with a phenylamide (5 and 6) or alkynamide linker (7) and their binding pose in the catalytic domain of TbrPDEB1. Key active site residues and the P-pocket are shown for clarity. NPD-008 (5) is displayed in blue, NPD-937 (6) in cyan and NPD-048 (7) in orange.
Chemistry
The previously reported synthetic pathway towards phthalazinone alkynamides contained several steps with low yield and long reaction times. 25, 27 Revision of these steps resulted in the design of a new synthetic route (Scheme 1) with reduced reaction times, easier purifications and improved yields. In this new scheme 2-bromoanisole was used in a Friedel-Craft acylation with maleic anhydride to obtain carboxylic acid 14 in good yield. The conversion towards the E-isomer was also reported by Onoue et al. 31 and confirmed by NMR based on the 3 Jcoupling constant of 15.4 Hz between the vinylic hydrogens, typical for trans alkene protons. The cyclohexene moiety was introduced by a Diels-Alder reaction with butadiene to form carboxylic acid 15 in quantitative yield. The subsequent condensation with hydrazine and alkylation with isopropylbromide was performed as reported previously. 25, 27 It was decided to install an isopropyl group instead of a cycloheptyl substituent of the phthalazinone scaffold for this series of alkynamides, as this modification has been shown to yield a small positive effect on the activity profile. 25, 27 Conversion of the stereochemical configuration from the trans-cyclohexene to the cis-cyclohexene occurs under strongly basic conditions. Comparison of the NMRspectra of trans-tetrahydrophthalazinone 16 with the cis-tetrahydrophthalazinone synthesized according to previous reported methods 25 showed distinct differences in shift of aromatic protons (spectra in Supporting Info).
Alkylation of 16 with excess of sodium hydride resulted in a fast conversion towards the cis-tetrahydrophthalazinone, which was confirmed by nuclear magnetic resonance (NMR) spectroscopy using Nuclear Overhauser Enhancement (NOE) experiments. Upon saturation of the signal of proton H4a in 15 and 16, a weak NOE correlation with H8a was observed in the NOE difference spectrum. Saturation of the signal of proton H4a in 17 resulted in a strong NOE correlation with H8a and thereby confirming the cis-configuration of 17 (spectra in Supporting Info). Furthermore, the observed 3 J-values of H4a are in agreement with the trans-isomer for 16 with one small and two large coupling constants ( 3 J = 14.6, 11.4 and 5.4 Hz), indicating one axialequatorial and two axial-axial positioned protons. 32 The opposite was observed for cis-isomer 17 with one larger and two smaller coupling constants ( 3 J = 11.5 and 2 × 5.8 Hz) as a result of one axial-axial coupling and two axial-equatorial protons. The alkyne functionality was introduced using combined Sonogashira/Hiyama reaction conditions with TMS-protected triethylorthopropiolate 18, which was synthesized in a Grignard reaction from TMS-acetylene in high yield, to obtain ethyl ester 19. The various amides were obtained by coupling the corresponding amines to ester 19 using AlMe 3 in DCM.
PDE-activity assay
The PDE-activity on TbrPDEB1 and hPDE4 of the synthesized alkynamides was measured to assess their potency and selectivity as TbrPDEB1 inhibitors. Aliphatic alkynamides 20-27 showed comparable submicromolar potencies against TbrPDEB1 in a pK i range of 6.0 to 6.5 (Table 1) . Most alkynamides showed similar or lower potency for hPDE4 compared to TbrPDEB1, with the best selectivity index (SI, TbrPDEB1 pK i -hPDE4 pK i ) observed for the tetrahydrofuranyl-substituted analogue 26 (SI = 0.5).
The alkynamides that contain aromatic rings in the tail group (11, 12 and 28-41, Table 2 ) showed in general higher potencies for TbrPDEB1 (pK i range 6.1-7.0) when compared to the aliphatic alkynamides. Interestingly, both compounds that were directly selected from the virtual screening (11 and 12) showed the lowest potency on TbrPDEB1 observed for the aromatic series of alkynamides. There was no difference observed between a furan and thiophene ring (28 and 30), both having a nanomolar potency against TbrPDEB1 (pK i = 6.9).
Introducing a methyl group on the furan (29) or elongating the tail group for the thiophene (31) slightly reduced the potency for TbrPDEB1. Implementing a thiazole ring (32) (33) (34) in the tail group did not improve the potency or selectivity of the alkynamides. Methylpyrrole 35 was equally potent against TbrPDEB1 as 2-methylfuran 28 and 2-methylthiophene 30, but with a slightly better SI ( Table 2 , SI = 0.7). Imidazole 36 with a more flexible tail displayed a reduced activity and selectivity.
The highest potencies were observed for pyridinyl alkynamides 38 (NPD-1169, pK i = 7.0) and 39 (NPD-1334, pK i = 7.0), which were slightly more potent than the benzyl analogue 37 (pK i = 6.8), while the less flexible 3-methoxyphenyl analogue 40 displayed a pK i of 6.7 against TbrPDEB1. Fluorophenyl 41 showed a slightly reduced potency and selectivity when compared with benzyl analogue 37.
When compared to the previously synthesized primary alkynamide 7 with a SI of −0.3 ( Fig. 4 ), most compounds (except 11) show a slightly improved selectivity index for TbrPDEB1 over hPDE4 and several compounds display a comparable selectivity to 5 (SI = 1.0). The SI observed for 39 was 0.8 log unit, making this 4-pyridinyl alkynamide approximately 6-times more potent against TbrPDEB1 than hPDE4.
Co-crystal structures in TbrPDEB1 and hPDE4
We successfully obtained co-crystal structures of 37, 40 and 41 (PDB: 6GXQ, 6RFN and 6RFW, respectively, Fig. 5 ) and the previously reported NPD-053 (42) and NPD-055 (43) (PDB: 6RB6 and 6RGK, respectively) in the catalytic domain of TbrPDEB1 and co-crystal structures of 37 and 42 bound in the catalytic domain of hPDE4 (PDB:
6HWO and 6RCW respectively). While our design indicated that decoration of the alkynamide nitrogen of 7 is possible in TbrPDEB1 because of the presence of the parasite-specific P-pocket, the crystal structures of 37 show that the amide substituent does not occupy the Ppocket ( Fig. 5A ).
While a bidentate interaction with the key Gln874 of TbrPDEB1 is maintained, the amide substituent folds back in a hydrophobic collapse. A highly similar binding pose is observed in the co-crystal structure of 37 in hPDE4 ( Fig. 5B ). The comparison of the co-crystal structures of 42 in hPDE4 and TbrPDEB1 gave a similar result (See Supporting Info). While the ligands do not seem to exploit the parasite-specific P-pocket, the crystal structures do not give an explanation for the improved activity profile for TbrPDEB1 over hPDE4. The tail groups seem to fold back towards Phe877 of the hydrophobic clamp, but no substantial additional interactions are observed. In addition, an overlay of the binding poses of 37, 40, 41, 42 and 43 in the catalytic domain of TbrPDEB1 ( Fig. 5C ) shows that they occupy the same space in the binding site (images of individual crystal structures can be found in the Supporting Info).
Surface plasmon resonance biosensor analysis
To increase our understanding of ligand-PDE binding and the molecular features that have an influence on the resulting activity profiles, we performed interaction analyses using a surface plasmon resonance (SPR) biosensor assay ( Fig. 6 ). Biotinylated proteins were captured by neutravidin, immobilized on CM5 chip surface. Interaction assays were performed by injecting suitable concentration series for each compound. Compounds 20 and 37 were injected for respectively 60 and 320 s to reach steady-state equilibrium and their dissociation was monitored (300 s for 20 and 900 s for 37) to determine the pK D values. The affinity of the unsubstituted alkynamide 20 at hPDE4D (pK D = 6.6 ± 0.1) was ∼0.5 log unit higher compared to the affinity obtained for its binding to TbrPDEB1 (pK D = 6.1 ± 0.1). Going from 20 to the benzyl substituted analog 37, the affinity for TbrPDEB1 (pK D = 7.1 ± 0.1) improved 10-fold, while at hPDE4D (pK D = 7.1 ± 0.1) the affinity of 37 was only 0.5 log-unit higher. These findings indicate that the benzyl substitution of the alkynamide has a pronounced effect on TbrPDEB1 binding, as 37 is equipotent at TbrPDEB1 and hPDE4. Interestingly, while the obtained crystal structures do not easily explain the improved biochemical activity profile of the new TbrPDEB1 inhibitors, the SPR biosensor analysis indicates noteable differences in binding kinetics, as a much slower off-rates for TbrPDEB1 and hPDE4 can be observed when comparing the dissociation kinetics of 20 and 37. The results indicate that binding kinetics represent an opportunity to design new compounds with improved activity profiles. We are currently developing in silico methods (including but not limited to molecular dynamics studies) to translate these kinetic binding data to molecular understanding.
Phenotypical data
All alkynamides were tested in vitro for their trypanocidal activity against T. brucei trypomastigotes ( Table 3 ). The best results were obtained for 37 and 39, which both displayed submicromolar activities and were not cytotoxic to MRC-5 cells. Aliphatic alkynamides (20) (21) (22) (23) (24) (25) (26) (27) showed a lower activity when compared to alkynamides with aromatic tail groups (11, 12 and 28-41), as observed in the biochemical assay.
As displayed in Fig. 7 , the alkynamides showed a good correlation (R 2 = 0.7) between TbrPDEB1 and T. brucei activity. No correlation was observed between important physicochemical properties (cLogP, cLogS and TPSA) and their anti-T. brucei activity (graphic representation in Supporting Info). Most alkynamides showed low or no cytotoxicity on MRC-5 cells, except imidazole 36 that displayed a substantially higher cytotoxicity when compared with other alkynamides. When compared to alkynamide 7 (CC 50 = 5.0) most decorated alkynamides show an improved cytotoxicity profile.
Intracellular real-time cAMP assay
To confirm on-target activity of 37 and 39 in live parasites, procyclic form trypanosomes expressing a FRET-based cAMP sensor were incubated with 1 and 10 µM inhibitor 37 and 39 ( Fig. 8 ). Both inhibitors induce a rapid and sustained increase in intracellular cAMP in . Biochemical activity against TbrPDEB1 and hPDE4 of all alkynamides and reference compounds NPD-008 (5) and NPD-048 (7) . The selectivity index (pK i TbrPDEB1 -pK i hPDE4) is indicated by colour. , and compound 37 binding to hPDE4D (C) and TbrPDEB1 (D). Inset shows steadystate affinity analyses of SPR biosensor interaction data; blank injections are also shown. Measurements using two independent biosensor chips and three different stock solutions indicate good reproducibility (see supplementary information).
the reporter cell line versus the negative control (DMSO), as indicated by an increase in 488/535 nm emission ratio. Both inhibitors were compared with a known non-selective TbrPDEB1 inhibitor (NPD-001), which was previously reported to increase intracellular cAMP levels in bloodstream and procyclic form trypanosomes. 18, 33 Both inhibitors 37 and 39 show a higher response at 1 µM when compared with reference inhibitor NPD-001 and an equal response at 10 µM.
To determine the activity of inhibitor 37 and 39 on bloodstream form trypanosomes, parasites were incubated with inhibitor 37 and 39 for 24-48 h prior to fixation and cellular analysis by fluorescence microscopy. After incubation with inhibitor 37 and 39, bloodstream form trypanosomes exhibit a lethal block in cytokinesis, indicated by multinucleated and multi-flagellated parasites (Fig. 9 ). The trypanocidal effects of 37 and 39 are in line with previous observations after genetic and pharmacological modulation of TbrPDEB1 and TbrPDEB2 expression or function in bloodstream form trypanosomes. 16, 19 
Conclusion
The structure-based design of alkynamide phthalazinones as TbrPDEB1 inhibitors delivered several compounds with a submicromolar activity against TbrPDEB1 and a modest selectivity over its human homologue hPDE4. Unexpectedly, alkynamide 37 did not show the predicted P-pocket occupation by the tail group in the co-crystal structure with TbrPDEB1 and a very similar binding mode was observed in the co-crystal structure with hPDE4. This observation indicates that targeting of the P-pocket of TbrPDEB1 is difficult to achieve with alkynamide tetrahydrophthalazinones. Moreover, the observed (moderate) selectivity of the benzyl and the two pyridinyl-substituted alkynamides 37, 38 and 39 suggests that other, as of yet unidentified interactions of PDE inhibitors with TbrPDEB1 and hPDE4 can also result in (moderate) parasite selectivity. The alkynamides show a good correlation between their biochemical activity against TbrPDEB1 and their in vitro activity against T. brucei parasites. Benzyl alkynamide 37 (NPD-1335) is 5-fold more potent against TbrPDEB1 (pK i = 6.9) than hPDE4 (pK i = 6.2) and displays a greatly improved cytotoxicity profile (pIC 50 T. brucei = 6.2 vs pCC 50 MRC-5 < 4.2) when compared to the unsubstituted alkynamide 7 (pIC 50 T. brucei = 6.0 vs pCC 50 MRC-5 < 5.0). Furthermore, incubation of procyclic forms with 37 and 39 results in elevation of the intracellular cAMP levels in the cells. In bloodstream forms, incubation with 37 and 39 leads to a block in cytokinesis, which is associated with formation of multiple flagella and nuclei, both supporting a PDE-mediated mode of action.
Experimental
Docking
The dockings were performed similar to the combined screening protocol as previously published for GPCRs. 30 In short, the dockings were performed using PLANTS 28 (version 1.2) and the resulting docking poses were post-processed with IFP 29 (version 2.2). Every molecule was docked 5 times generating 10 docking poses during each iteration (speed setting 2, RMSD 1.0) into each of the three crystal structures (chain B for 5G2B and 5L8Y and chain A for 6FTM) based on the pocket definition as defined for PDEStrIAn. 34 All docking poses were scored using the ChemPLP scoring function and only poses with a score ≤−90 were further investigated. The positioning of the core scaffold was evaluated by performing an IFP similarity comparison to the co-crystallized ligands limited to solely the residues in the direct vicinity of the core scaffold. Poses with an IFP score lower than 0.5 or where the ligand did not interact with the conserved glutamine (Q.50) or the hydrophobic clamp (HC.32, HC.52) were removed. A final interaction filter was applied to select only those binding modes in which the Q2 pocket was targeted by having at least one IFP contact with Q2.45 or Q2. 46 . From the initial combinatorial library of 16,153 alkynamides 2291 compounds remained for further processing.
Protein production
Cloning, expression and purification of recombinant TbrPDEB1 and hPDE4D catalytic domains were performed as previously described. 25 
Crystallization, data collection and structure determination
Apo crystals of TbrPDEB1 and hPDE4D were grown in 24 well XRL plates (Molecular Dimensions, Newmarket, Suffolk, UK) by vapor diffusion hanging drop technique. Typically, protein and crystallization solution were mixed in 1:1 ratio and drops were setup against 500 μL reservoir solution. Crystals of TbrPDEB1 were obtained in a condition containing 20% PEG 3350, 400 mM sodium formate, 300 mM guanidine and 100 mM MES pH 6.5 at 4°C and soaked with different inhibitors to obtain protein-inhibitor complexes. hPDE4D crystals 37 and AIMLESS, 38 or were integrated using iMOSFLM 39 and reduced using POINTLESS, AIMLESS and TRU-NCATE, all of which are part of CCP4 suite. 40 Structures of inhibitor complexes with TbrPDEB1 and hPDE4D were determined by molecular replacement in CCP4 suite program PHASER 41 by using the respective apo models (TbrPDEB1, PDB id: 4I15; hPDE4D, PDB id: 3SL3) as search templates. Stereochemical restrains for the inhibitors were generated by ACEDRG available within the CCP4 package and ligand fitting and model adjustment were carried out in COOT 42 followed by their refinement in REFMAC. 43 Data processing and refinement statistics are given in Tables 4 and 5 . Structural figures were prepared with PYMOL 44 . Coordinates of the structures have been deposited to the RCSB Protein Data Bank with following accession codes:
Phosphodiesterase activity assays
Phosphodiesterase activity assays are performed using the PDELight™ HTS cAMP phosphodiesterase Kit (Lonza, Walkersville, USA): The assay is performed at 25°C in non-binding, low volume 384 wells plates (Corning, Kennebunk, ME, USA). PDE activity measurements (TbrPDEB1_CD; K m 3.45 µM, hPDE4B_CD; K m 13.89 µM) are made in 'stimulation buffer' (50 mM Hepes, 100 mM NaCl, 10 mM MgCl, 0.5 mM EDTA, 0.05 mg/mL BSA, pH 7.5). Single concentration measurements are made at 10 µM inhibitor concentration (triplo measurements/assay, n = 2). Dose response curves are made in the range 100 µM−10 pM (triplo measurements/assay, n = 3). Compounds are diluted in DMSO (final concentration 1%). Inhibitor dilutions (2.5 µL) are transferred to the 384 wells plate, 2.5 µL PDE in stimulation buffer is added and mixed, 5 µL cAMP (at 2 × K m up to 20 µM) is added and the assay is incubated for 20 min at 300 rpm. The reaction is terminated by then addition of 5 µL Lonza Stop Buffer supplemented with 10 µM NPD-001. Then 5 µL of Lonza Detection reagent (diluted to 80% with reaction buffer) is added and the reaction incubated for 10 min at 300 rpm. Luminescence is read with a Victor3 luminometer using a 0.1 s/well program. RLUs were measured in comparison to the DMSO-only control, NPD-001 always was taken along as positive control as a PDE inhibitor. The K i values of the inhibitors analyzed are represented as the mean of at least three independent experiments with the associated standard error of the mean (SEM) as indicated.
Phenotypic cellular assays
For the cellular assays, the following reference drugs were used as positive controls: suramin (Sigma-Aldrich, Germany) for T. brucei (pIC 50 = 7.4 ± 0.2, n = 5), and tamoxifen (Sigma-Aldrich, Germany) for MRC-5 cells (pCC 50 = 5.0 ± 0.1, n = 5). All compounds were tested at five concentrations (64, 16, 4, 1 and 0.25 µM) to establish determination of the IC 50 and CC 50 . Data are represented as the mean of duplicate experiments ± S.E.M. The final concentration of DMSO did not exceed 0.5% in the assays.
In vitro antitrypanosomal assay. T. brucei Squib-427 strain (suraminsensitive) was cultured at 37°C and 5% CO 2 in HMI-9 medium, supplemented with 10% heat-inactivated fetal calf serum (FCSi). About 1.5 × 10 4 trypomastigotes were added to each well and parasite growth was assessed after 72 h at 37°C by adding resazurin. Viability was assessed fluorimetrically 24 h after the addition of resazurin. Fluorescence was measured (excitation 550 nm, emission 590 nm) and the results were expressed as percentage reduction in viability compared to control.
In vitro MRC-5 cytotoxicity assay. MRC-5 SV2 cells, originally from a human diploid lung cell line, were cultivated in MEM, supplemented with L-glutamine (20 mM), 16.5 mM sodium hydrogen carbonate and 5% FCSi. For the assay, 10 4 MRC-5 cells/well were seeded onto the 96well test plates containing the pre-diluted sample and incubated at 37°C and 5% CO 2 for 72 h. Cell viability was assessed fluorimetrically 4 h after the of addition of resazurin. Fluorescence was measured (excitation 550 nm, emission 590 nm) and the results were expressed as percentage reduction in cell viability compared to control.
Intracellular cAMP and fluorescence microscopy
Cell lines
Procyclic 2913 T. b. brucei 45 were cultivated in SDM-79 supplemented with 5% FCSi 46 Bloodstream-form T. b. brucei 221 single marker cell line 45 were cultivated in HMI-9 medium supplemented with 10% FCSi 46 The cAMP FRET reporter cell line was developed by transfecting 2913 procyclic form T. b. brucei with linearized pLEW-100 containing epac1camps. Selection for transfected cells and cloning by limited dilution was done as published previously. 46 Expression of epac1-camps was validated using fluorescence microscopy.
Plasmids
For tetracycline inducible expression of the cAMP FRET sensor, the Epac1camps sensor 47 was cloned into pLEW-100 45 as described. 33 
Chemicals
NPD-001, 37, 39 were dissolved in DMSO to 1 and 10 mM and stored at −80°C.
FRET assay
cAMP FRET assays were performed in triplicates for each time point and 3 independent experiments, as described previously 33 : As controls, NPD-001 (positive control, 18 and DMSO (solvent for 37, 39, NPD-001)) were included. The following modifications to the published method 33 were made: the cAMP reporter cell line was cultivated in SDM-79 containing 5% FCSi. After induction of Epac1-camps expression with tetracycline 46 for 24 h-48 h, the cells were washed once and resuspended in PBS containing 5% FCSi to 1.5 × 10 8 cells/mL. 150 µL of cells was added to each well of a 96-well black microtiter plate. 50 µL of NPD-001, 37, 39 and DMSO diluted in PBS containing 5% FCSi was added to the wells (final concentration of compounds: 10 µM).
Microscopy
Bloodstream-form T. b. brucei 221 single marker cell line were cultivated for 24 h in the presence of 1 µM NPD-001, 37, 39 or DMSO as control. Methodology used for cell fixation and staining has been described previously, 48 with the following modifications: blocking and antibody staining was done in PBS containing 5% bovine serum albumin (BSA). Antibodies used were rat anti-PFR 1:500 49 and anti-rat Alexa594 1:500 (Invitrogen). NucBlue Fixed Cell Stain (Invitrogen) was added to Vectashield mounting medium (for DNA stain). Images were acquired using a Leica confocal microscope and standard procedures. Images were processed using ImageJ.
Surface plasmon resonance
All experiments were performed with a Biacore T200 surface plasmon resonance biosensor instrument (GE healthcare). Proteins were immobilized on CM5 series S sensor chips. Consumables were obtained from GE Healthcare. All solutions were freshly prepared, degassed, and filtered. The neutravidin immobilization was run on HBS-N at a flowspeed of 10 µL/min at 25°C. The matrix of the sensor chip was activated by injecting on all flow channels a mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 1-ethyl-3-(3-(dimethylamino) propyl) carbodiimidehydrochloride (EDC) at a flow rate of 10 µM for 420 s. Subsequently, neutravidin (0.30 mg/mL) in a 10 mM NaAc solution (pH 5.0) was injected for 120 s. Unreacted activated groups of the dextran matrix were deactivated by injection of ethanolamine.HCl (1 M) for 420 s.
The catalytic domains of hPDE4D and TbrPDEB1 were produced and purified as previously described. 25 the proteins were buffer exchanged using a Amicon Ultra 0.5 mL centrifugal filter (Merk) to HBS-N, 5% glycerol (v/v), 4 µM MgCl 2 ·6H 2 O, 100 nM ZnCl 2 , 2 mM 2-mercaptoethanol and diluted to 1 mg/mL. EZ-Link Sulfo-NHS-Biotin (Thermo Fisher Scientific) was diluted to 1.5 mM in the same buffer, mixed with the protein in a 1:1 M ratio, and incubated at 4°C overnight. Biotinylated proteins were buffer exchanged to 0.5 M Tris-HCl (pH 8.0), 150 mM NaCl, 4 mM MgCl 2 ·6H 2 O, 100 nM ZnCl 2 , 5% glycerol (v/v), 2 mM 2-mercaptoethanol, and desalted using 0.5 mL Zeba Spin desalting columns (Thermo Scientific). Proteins were diluted to 0.5 mg/ mL and injected on the flow channels until 3000 RU in the same buffer at 15°C. Biocytin (0.05 mg/mL) was injected for 120 s on all flow channels at 15°C.
All compounds were dissolved in DMSO (stock solutions of 10 mM) and diluted in 0.5 M Tris-HCl (pH 8.0), 150 mM NaCl, 4 mM MgCl 2 ·6H 2 O, 100 nM ZnCl 2 , 5% glycerol (v/v), 2 mM 2-Mercaptoethanol, 0.005% Tween-20 (v/v), 2% DMSO (v/v). Suitable concentration series and injection times were determined for each compound separately. In multicycle experiments, a 7-point concentration range of each compound was measured. On a first CM5 chip, a first stock solution was used to obtain a dose response curve in duplicate. On a second CM5 chip, two other independent stock solutions were used to measure dose response curves in duplicate. Compound 20 was injected for 60 s and its dissociation was monitored for 300 s. Compound 37 was injected for 420 s and its dissociation was monitored for 900 s. All titrations were run at 25°C at a flow speed of 50 µL/min. Data analyses were performed with Scrubber2. Signals were subtracted from reference surface and blanc injections. DMSO correction was performed. The affinity was determined by fitting a Langmuir binding equation to steady state binding signals at different concentrations. All SPR experiments are shown in the Supplementary data with individually measured pK D and the error reported is the error in the fit of the binding isotherm.
Chemistry
General
All reagents and solvents were obtained from commercial suppliers and were used as received. All reactions were magnetically stirred and carried out under an inert atmosphere. Reaction progress was monitored using thin-layer chromatography (TLC) and LC-MS analysis. LC-MS analysis was performed on a Shimadzu LC-20AD liquid chromatograph pump system, equipped with an Xbridge (C18) 5 µm column (50 mm, 4.6 mm), connected to a Shimadzu SPD-M20A diode array detector, and MS detection using a Shimadzu LC-MS-2010EV mass spectrometer. The LC-MS conditions were as follows: solvent A (water with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic acid), flow rate of 1.0 mL/min, start 5% B, linear gradient to 90% B in 4.5 min, then 1.5 min at 90% B, then linear gradient to 5% B in 0.5 min, then 1.5 min at 5% B; total run time of 8 min. Silica gel column chromatography was carried out with automatic purification systems using the indicated eluent. Reversed phase column purification was performed on Grace Davison iES system with C18 cardridges (60 Å, 40 μm) using the indicated eluent. Nuclear magnetic resonance (NMR) spectra were recorded as indicated on a Bruker Avance 500 (500 MHz for 1 H and 125.8 MHz for 13 C) instrument equipped with a Bruker CryoPlatform, or on a Bruker Avance III HD (600 MHz for 1 H) instrument equipped with a Bruker CryoPlatform. Chemical shifts (δ in ppm) and coupling constants (J in Hz) are reported with residual solvent as internal standard (δ 1 H NMR: CDCl 3 7.26; DMSO-d 6 2.50; δ 13 C NMR: CDCl 3 77.16; DMSO-d 6 39 .52). Abbreviations used for 1 H NMR descriptions are as follows: s = singlet, d = doublet, t = triplet, q = quintet, hept = heptet dd = doublet of doublets, dt = doublet of triplets, tt = triplet of triplets, m = multiplet, app d = apparent doublet, br = broad signal. Exact mass measurement (HRMS) was performed on a Bruker micrOTOF-Q instrument with electrospray ionization (ESI) in positive ion mode and a capillary potential of 4,500 V. Systematic names for molecules were generated with ChemBioDraw Ultra 14.0.0.117 (PerkinElmer, Inc.). The reported yields refer to isolated pure products and yields were not optimized. The purity, reported as the LC peak area % at 254 nm, of all final compounds was ≥95% based on LC-MS. All compounds are isolated as a racemic mixture of cisenantiomers. (14) . To an ice-cooled mixture of 1-bromo-2-methoxybenzene (65 mL, 0.52 mol) and furan-2,5-dione (77 g, 0.78 mol) in DCM (465 mL) was added AlCl 3 (84 g, 0.63 mol). The reaction mixture was stirred at rt overnight. The orange suspension was quenched in 3 M aq. HCl (1.5 L) and extracted using EtOAc (4 × 1 L). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated to obtain a dark yellow solid. Trituration with Et 2 O provided the product as a light yellow solid (97.5 g, 66% (15) . A mixture of 14 (70.0 g, 221 mmol) and buta-1,3-diene in THF (∼13% w/w, 150 mL, 300 mmol) was divided over 8 microwave vials. Each vial was stirred under microwave irradiation at 140°C for 30 min (the internal pressure reached ∼ 10 bar). The reaction mixtures were pooled and concentrated in vacuo to obtain the crude product. Trituration with toluene provided the product as a white solid (72. 4 (16) . A solution of 15 (70 g, 0.21 mol) and hydrazine monohydrate (32 mL, 0.62 mol) in EtOH (400 mL) was stirred at reflux for 4 h. The reaction mixture was cooled in the refridgerator and filtered to obtain the pure product as a white solid (60 g, 86%). Note: Partial conversion of stereochemistry during the condensation reaction was observed only once (out of 5) during a small scale reaction (< 3 mmol (17) . To a solution of 16 (50.0 g, 0.15 mol) in DMF (500 mL) was added NaH (15 g, 0.37 mol) and the reaction mixture was stirred at rt for 30 min. 2-bromopropane (21 mL, 22 mmol) was added to the reaction mixture and the reaction mixture was stirred at rt for 4 h. The reaction mixture was quenched with aq. HCl (0.5 M, 1.5 L) on ice. The suspension was filtered and the residue was dissolved in MeOH/DCM. The solution was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was triturated with Et 2 O to obtain the product as white crystals ( Trimethyl(3,3,3-triethoxyprop-1-yn-1-yl) silane (18) . Magnesium (1.38 g, 56.7 mmol) was activated using a mortar and pestle and was suspended in dry Et 2 O (25 mL). 2-bromopropane (5.33 mL, 56.7 mmol) was slowly added to the stirring reaction mixture while cooling with water (the reaction mixture starts to reflux). The reaction mixture was stirred in a cold water bath for 30 min prior to the addition of ethynyltrimethylsilane (6.68 mL, E. de Heuvel, et al. Bioorganic & Medicinal Chemistry 27 (2019) 4013-4029 47.3 mmol). This reaction mixture was stirred for an additional 30 min to form a thick grey suspension, which was diluted with Et 2 O (25 mL) prior to slow addition of tetraethoxymethane (10.9 mL, 52.0 mmol). After 1 h the reaction mixture turned into a dark brown/colourless mixture (two phases). The reaction mixture was poured in saturated aq. NH 4 Cl (500 mL) and was extracted with Et 2 O (2 × 500 mL). The organic phase was concentrated and the product was isolated as a light yellow liquid (10.5 g, 93%). 1 H NMR (500 MHz, DMSO-d 6 ): δ 3.55 (q, J = 7.1 Hz, 6H), 1.12 (t, J = 7.2 Hz, 9H), 0.18 (s, 9H). 13 Ethyl 3-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a -hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolate (19) . To a N 2 -purged solution of 17 (0.50 g, 1.3 mmol) in DMF (2 mL) and Et 3 N (2 mL) was added subsequently 18 (0.65 g, 2.7 mmol), PdCl 2 (dppf) (49 mg, 0.66 mmol), CuI (25 mg, 0.13 mmol) and CsF (0.30 g, 1.99 mmol). The mixture was stirred in the microwave at 120°C for 4 h. The reaction mixture was poured in 1 M aq. HCl (250 mL) and extracted with EtOAc (2 × 250 mL). The organic phase was washed with brine (250 mL), dried over MgSO 4 , filtered and concentrated to obtain the crude product as a brown solid. The crude product was purified using flash column chromatography (0-50% EtOAc/ Hept). The product was obtained as a light yellow solid (0.37 g, 70%).
Synthetic procedures 4.8.2.1. (E)-4-(3-Bromo-4-methoxyphenyl)-4-oxobut-2-enoic acid
Trans-6-(3-Bromo-4-methoxybenzoyl)cyclohex-3-ene-1-carboxylic acid
Cis-4-(3-Bromo-4-methoxyphenyl)-2-isopropyl-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one
LC (20) . Ester 19 (0.50 g, 1.27 mmol) was dissolved in a solution of NH 3 in MeOH (7 M, 4 mL, 28.0 mmol) and stirred at rt for 2 h. The reaction mixture was concentrated and the crude product was purified using flash column chromatography (gradient: 0-50% EtOAc/Hept). The product was obtained as a white solid (390 mg, 84%).
LC (5 equiv.) and the corresponding amine (2.5 equiv.) (3 equiv. of Et 3 N was added for HCl salts). AlMe 3 (2.5 equiv.) was slowly added and the reaction mixture was stirred at rt overnight. The reaction mixture was carefully poured in 1 M aq. HCl (100 mL) and extracted with EtOAc (100 mL). The organic phase was washed with brine (100 mL), dried over MgSO 4 , filtered and concentrated to obtain the crude product as a brown solid. The crude product was purified using flash column chromatography. 4, 4a, 5, 8, 8a -hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide (21) . This compound was synthesized according to the general procedure using 19 (0.25 g, 0.63 mmol) and butan-1-amine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 0-50%) to obtain a white solid (182 mg, 68%).
LC (22) . This compound was synthesized according to the general procedure using 19 (0.20 g, 0.51 mmol) and cyclopropylmethanamine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 0-50%) to obtain a white solid (105 mg, 49%).
N-(Cyclopropylmethyl)-3-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,-8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide
LC (5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a- hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide (24) . This compound was synthesized according to the general procedure using 19 (0.20 g, 0.51 mmol) and 3-aminopropanenitrile as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 0-50%) to obtain a white solid ( 1-(3-(5-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a -hexahydrophthalazin-1-yl)-2-methoxyphenyl)propioloyl)azetidine-3-carbonitrile (25) . This compound was synthesized according to the general procedure using 19 (0.20 g, 0.51 mmol) and azetidine-3-carbonitrile. HCl as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 0-50%) to obtain a white solid (126 mg, 58%).
LC (27) . This compound was synthesized according to the general procedure using 19 (0.10 g, 0.25 mmol) and morpholine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 0-50%) to obtain a white solid (56 mg, 51%).
Cis-2-Isopropyl-4-(4-methoxy-3-(3-morpholino-3-oxoprop-1-yn-1-yl)phenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one
LC 4, 4a, 5, 8, (11) . This compound was synthesized according to the general procedure using 19 (0.10 g, 0.25 mmol) and 2-methyl-2H-1,2,3triazol-4-amine.HCl as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 10-80%) to obtain a white solid (42 mg, 37% N-(1-(3-Cyanopropyl) (12) . This compound was synthesized according to the general procedure using 19 (0.10 g, 0.25 mmol) and 4-(3-amino-1Hpyrazol-1-yl)butanenitrile as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 10-80%) to obtain a white solid ( oxo-3,4,4a,5,8 ,-8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide (28) . This compound was synthesized according to the general procedure using 19 (0.20 g, 0.51 mmol) and furfurylamine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 0-50%) to obtain a white solid (112 mg, 50% .99-6.91 (m, 2H), 6.88 (dd, J = 3.3, 1.2 Hz, 1H), 6.36 (t, J = 6.1 Hz, 1H), 5.81-5.62 (m, 2H), 5.04 (p, J = 6.6 Hz, 1H), 3.91 (s, 3H), 3.64 (q, J = 6.6 Hz, 2H), 3.25 (dt, J = 11.5, 5.7 Hz, 1H), 3.10 (t, J = 6.8 Hz, 2H), 3.05-2.95 (m, 1H), 2.72 (q, J = 7.7, 5.9 Hz, 1H), 2.25-1.97 (m, 3H), 1.32 (dd, J = 6.6, 2.6 Hz, 3H), 1.20 (dd, J = 6.7, 2.9 Hz, 3H). 13 (34) . This compound was synthesized according to the general procedure using 19 (0.10 g, 0.25 mmol) and (2,4dimethylthiazol-5-yl)methanamine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 10-80%) to obtain a white solid (36 mg, 29%).
N-(Furan-2-ylmethyl)-3-(5-(cis-3-isopropyl-4-
LC 
3-(5-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)-N-((1-methyl-1H-pyrazol-4-yl)methyl)
propiolamide (35) . This compound was synthesized according to the general procedure using 19 (0.15 g, 0.38 mmol) and (1-methyl-1Hpyrazol-4-yl)methanamine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 10-80%) to obtain a white solid (73 mg, 42%).
LC-MS (ESI): t R = 4.37 min, area: > 98%, m/z: 460 [M+H] + . N-(3-(1H-Imidazol-1-yl) propyl)-3-(5-(cis-3-isopropyl-4-oxo-3,-4,4a,5,8,8a-hexahydrophthalazin-1-yl)-2-methoxyphenyl)propiolamide (36) . This compound was synthesized according to the general procedure using 19 (0.15 g, 0.38 mmol) and 3-(1H-imidazol-1-yl) propan-1-amine as the corresponding amine. Column chromatography was performed using EtOAc/n-hept (gradient: 10-100%)to obtain a white solid (101 mg, 56%).
LC-MS (ESI): t R = 3.59 min, area: > 98%, m/z: 474 [M+H] + .
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